2019 DEA Policy Safety 
Canna Law Blog
MAY 7, 2020
At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. For two decades, U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 22, 2020
It also directs the Commission to research “important current issues facing law enforcement and the criminal justice system,” and recommends a variety of subjects for study, such as, but not limited to” There is no direct mention of cannabis but a senior DEA appointment we would suggest is a message in itself. DEA Chief of Operations D.
Veriheal
DECEMBER 1, 2022
The SAFE Banking Act was introduced in 2019 and has passed the House seven times, but it still needs to make it to the Senate floor. This bill also directs the DEA to register manufacturers and distributors of CBD or marijuana for commercial production of an approved drug that contains marijuana or its derivative.
Cannabis Law Report
JULY 27, 2022
As a Schedule I substance under the Controlled Substances Act, marijuana has a high potential for abuse and no currently accepted medical use in treatment in the United States and lacks accepted safety for use under medical supervision. Food and Drug Administration (FDA) has federal authority to approve drugs for medicinal use in the U.S.
Cannabis Law Report
MAY 29, 2022
In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.
Expert insights. Personalized for you.
71 
Let's personalize your content